Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + nivolumab + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of carboplatin (a platinum-based chemotherapy), nivolumab (an anti-PD-1 monoclonal antibody immunotherapy), and paclitaxel (a taxane chemotherapy). This regimen combines traditional cytotoxic chemotherapy with immune checkpoint inhibition to treat various cancers, particularly non-small cell lung cancer (NSCLC). The combination has shown improved efficacy compared to chemotherapy alone in both neoadjuvant and metastatic settings.
- Other names
- nivolumab plus paclitaxel plus carboplatin
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carboplatin + nivolumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + nivolumab + paclitaxel.